Thus, our studies suggest that SPOP would like to play dual functions to modulate AKT kinase activity either by targeting PTEN to activate AKT in ccRCCs or by targeting PDK1 to repress AKT in prostate cancer. The gene discussed is PTEN; the disease is prostate carcinoma.